Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL

Leuk Lymphoma. 2021 Apr;62(4):992-994. doi: 10.1080/10428194.2020.1846735. Epub 2020 Nov 21.

Authors

Dale Jobson^{1

2}, Christopher J McCormack^{1

3}, Emma Hiscutt¹, Constantine Tam^{4

5}

Affiliations

¹ Department of Dermatology, Peter MacCallum Cancer Centre, Melbourne, Australia.
² University of Edinburgh, Edinburgh, United Kingdom.
³ Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁴ Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
⁵ Department of Medicine, University of Melbourne, Melbourne, Australia.

PMID: 33222565
DOI: 10.1080/10428194.2020.1846735

No abstract available

Publication types

Letter

MeSH terms

Anemia, Hemolytic, Autoimmune* / diagnosis
Anemia, Hemolytic, Autoimmune* / drug therapy
Humans
Ipilimumab / adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell* / complications
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Melanoma* / complications
Melanoma* / drug therapy
Nivolumab
Skin Neoplasms* / drug therapy

Substances

Ipilimumab
Nivolumab